Ranju Bansal
Panjab University, India
Title: Development of xanthines as adenosine A2A receptor selective antagonists: A systematic approach towards novel nondopaminergic therapy for Parkinson’s disease
Biography
Biography: Ranju Bansal
Abstract
Adenosine receptors represent a new promising target for the development of various drug candidates for the treatment of a wide range of biological disorders. Currently four AR subtypes A1, A2A, A2B and A3 have been recognized and pharmacologically characterized. Adenosine A2A receptor antagonism represents a novel non-dopaminergic approach in the treatment of Parkinson’s disease. Substituted xanthines represent the most potent class of adenosine receptor (AR) antagonists reported to date. Xanthine scaffold represents itself as a privileged motif, which offers numerous modifications at 1-, 3-, 7-, and 8-positions for the development of new potent and selective AR ligands. SAR studies have established that the structural modifications at 1- and 3-positions of the xanthine nucleus greatly affect the binding ability of the compounds for adenosine receptors. It has also been observed that the most remarkable alterations in potencies of the xanthines as antagonists of adenosine receptors result from appropriate substitution at the 8-position of this heterocyclic system. The current study describes a systematic approach to design and synthesize a new series of 1,3,7,8-tetrasubstituted xanthines as potent and selective adenosine A2A receptor ligands for the treatment of Parkinson’s Disease.
